Transplacental passage of vancomycin in the ex vivo human perfusion model. by Hnat, Michael D et al.
Transplacental passage of vancomycin in the ex vivo human
perfusion model
Presented at the Annual Scientiﬁc Meeting and Symposium of the Infectious Diseases Society
for Obstetrics and Gynecology, Hyannis, Massachusetts, MA, August 7–9, 2003
Michael D. Hnat, Julie Gainer, Roger E. Bawdon and George D. Wendel Jr
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas,
Dallas, TX
Objectives: To determine maternal–fetal transplacental passage of vancomycin in the ex vivo human placental
perfusion model.
Methods: Six term placentas were collected immediately after delivery and perfused with physiologic medium
using the single cotyledon perfusion system. Vancomycin was added to the maternal medium and perfused
through the maternal circulation of the cotyledon. Over a 1-h period in an open system, samples of the
perfusate were collected at deﬁned intervals from the fetal venous catheter and from the maternal efﬂuence to
assess vancomycin transfer. Thereafter, the system was closed for 1–5 h to establish accumulation. Transport
fraction and clearance indexes were calculated by perfusing antipyrine
14C (positive control). Vancomycin was
estimated by high pressure liquid chromatography and antipyrine
14C concentration was determined by liquid
scintillation.
Results: Mean vancomycin maternal peak and trough concentrations ranged from 30.0 to 51.5 mg/ml and 7.7 to
16.4 mg/ml, respectively. Clearance indexes were minimal with a mean peak range of 0.000–0.080 and a mean
trough range of 0.00–0.17. For each placenta, transport fraction for antipyrine
14C was 41.85 with a single pass
of 440%. No accumulation of vancomycin was noted when the system was closed for 1–5 h. The mean peak
clearance index was zero after perfusing the placenta for up to 5 h with 35.8 mg/ml of vancomycin.
Conclusion: Transplacental passage of vancomycin was minimal in the ex vivo human placental perfusion model,
with no detectable accumulation.
Key words: VANCOMYCIN;P LACENTA;F ETUS;B ETA STREPTOCOCCUS;P REGNANCY
In 2002, the Centers for Disease Control released
new guidelines for the prevention of group B
streptococcal (GBS) disease in the neonate
1. The
American College of Obstetricians and Gynecol-
ogists had concurred with their recommendations
which include universal prenatal culture-based
screening at 35–37 weeks together with updated
chemoprophylaxis regimens for women with
penicillin allergies
2. Penicillin remains the ﬁrst-
line agent for intrapartum prophylaxis. Cefazolin
is recommended for women with a reported
penicillin allergy at low risk for complications
1–4.
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DOI: 10.1080/10647440400009821Clindamycin or erythromycin is indicated for
those who are penicillin-allergic and are at high
risk for anaphylaxis or at high risk for anaphylaxis
complications secondary to certain medical con-
ditions such as asthma
1.
Resistance of GBS isolates to erythromycin and
clindamycinhasincreasedoverthepastfewyears
5–
8. Therefore, susceptibility testing to these anti-
biotics is recommended in the new GBS
prophylaxis guidelines. Vancomycin is now ad-
vised for isolates that show in vitro resistance to
clindamycinor erythromycinor incases wherethe
susceptibility of the prenatal isolate is unknown
1.
Data are lacking on the relative effectiveness of
vancomycin for the prevention of GBS in the
neonate. In addition, information regarding
vancomycin pharmacokinetics in pregnancy is
limited. Two studies have observed transplacental
crossing of vancomycin in women with amnio-
nitis when administered over several days
9,10.
Bourget and colleagues investigated transplacental
transfer of vancomycin in a gravid woman with
amnionitis at 26 weeks
9. Reyes and others found
adequate vancomycin levels in 8 of 10 pregnant
women with amnionitis in the second and third
trimester
10. It is unknown whether vancomycin
crosses from the maternal to the fetal circulation
in a term placenta without infection. Therefore,
our objective was to quantify the maternal to fetal
transplacental passage of vancomycin in the non-
infected ex vivo human placental perfusion model.
MATERIALS AND METHODS
Term placentas were collected from either
Cesarean sections or vaginal deliveries in accor-
dance with the University of Texas Southwestern
Medical Center Institutional Review Board for
Human Studies guidelines, and transported to the
laboratory in normal saline immediately after
delivery.
The single cotyledon placental perfusion
system was used as described by Chalier
11. A fetal
artery and vein on the chorionic plate were
cannulated with 3.0 F and 5.0 F catheters,
respectively. The fetal circulation of the selected
cotyledon was gently perfused with Eagle’s
minimal essential media plus 3% bovine albumin
and 0.5 to 1.0 units/ml of heparin (Sigma
Chemical Co, St Louis, MO). The cotyledon
was initially examined for vascular integrity.
The localized cotyledon and surrounding
placental tissue were transferred to a tempera-
ture-controlled chamber (378C) where the fetal
circulation was perfused in a closed system at 4.5–
5.0 ml/min for 20 min to remove any residual
blood and to stabilize perfusion pressure at 35–
50 mmHg. Those placental cotyledons that failed
to reach a stable baseline pressure or were found to
haveavascularleakwerediscarded.Lastly,two18-
gauge needles were inserted into the intervillous
space of the cotyledon to re-establish the maternal
circulation. Maternal ﬂow rate was 17 ml/min.
The maternal and fetal compartments consisted
of 150 ml Eagle’s minimal essential medium
(pH 7.2–7.4), aerated with 95% oxygen and 5%
carbon dioxide and continually mixed by mag-
netic stirring bar. Transfer studies were performed
with vancomycin hydrochloride (Sigma). Vanco-
mycin was added to the maternal medium in
concentrations similar to maternal serum peak and
trough levels. In addition, experiments were ﬁrst
conducted in an open-open system to determine
transport fraction, then in a closed-closed recir-
culation system to determine accumulation. The
clearance index and accumulation of vancomycin
were also determined. Fluid aliquots from both
maternal and fetal compartments were collected
for analysis.
A total of 6 placentas met criteria for inclusion
in the study. A trough transfer study for
vancomycin was performed in 1 placenta and a
peak study in 1 other. Studies were completed
ﬁrst in an open system for 2 h and then in a closed
system. Both peak and trough transfer studies
were conducted in the other 4; trough studies
were performed in an open system and then in a
closed system, followed by peak studies in an
open system and then in a closed system.
Lastly, transport fraction and clearance indexes
were determined for each placenta by means of
the
14C antipyrine reference method of Chalier
5.
Placentas were studied in a non-recirculating
(open) system for 60 min to determine the
transport fraction of
14C antipyrine. Greater than
40% maternal–fetal transfer of antipyrine was
considered an indication of a successful maternal–
fetal match.
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14C concentra-
tions were measured by high pressure liquid
chromatography (HPLC) and liquid scintillation,
respectively. Reproducibility studies on the
vancomycin assay were performed. The HPLC
analysis of vancomycin was carried out on Waters
Associate instruments (Medford, MA). For HPLC
analysis, the perfusion sample was extracted with
0.5 ml of 10% trichloroacetic acid. The samples
and standards were mixed and centrifuged at 2000
6 g for 10 min. The clear extract was injected
into a Phenomenex C18 m Bond-a-pak column
(Torrance, CA). For HPLC, pH was 6.1 at a
sensitivity of .005 AU and a detector wavelength
of 2902. The buffer ﬂow rate was 2.0 ml/min and
an injection volume of 80 ml was used. The
retention time was about 6.0 min. All concentra-
tions of vancomycin were determined by
measuring the peak height of the standards and
specimen. The HPLC method was validated; the
reproducibility data are not shown.
RESULTS
For the HPLC determination of vancomycin
concentrations, reproducibility studies provided
values with a minimum sensitivity of 0.1 mg/ml,
and within-batch and between-batch reproduci-
bility of 490%. Transport fraction and clearance
indexes of vancomycin were determined at two
concentrations, peak and trough. For the maternal
efﬂuence, peak and trough levels are shown in
Table 1. The mean trough level was 11.7 mg/ml
with a range of 7.7–16.4 mg/ml, and the mean
peak level was 37.2 mg/ml with a range of 30.0–
51.5 mg/ml. At trough levels, the concentration
of vancomycin in the fetal circulation was below
the minimum sensitivity of the assay (50.1 mg/
ml) in 3 of the 5 trough levels and in 2 of the 5
peak levels. Thus, the clearance index could only
be calculated in the studies where vancomycin
concentrations were detected in the fetal circula-
tion. When the concentration of vancomycin was
not detected in the fetal concentration, the
clearance index was considered zero. For both
peak and trough concentrations, the clearance
indexes were minimal (Table 2).
The transport factor for antipyrine
14C was
41.85 with a single pass transfer greater than
40% for each placenta. When the system was
closed for 1 to 5 h, no fetal accumulation was
noted for peak and trough concentrations of
vancomycin.
DISCUSSION
Our data suggest that the clearance index of
vancomycin is low at both peak and trough
concentrations in the ex vivo placental perfusion
model. However, preliminary data from a present
study in our lab suggest a higher clearance index
of vancomycin in vivo. Certain aspects of the
model may have biased the results: for example,
vancomycin precipitates when mixed with more
than 1 unit/ml heparin
12,13. Although the media
used in this experiment contained less than or
equal to 1.0 unit/ml of heparin, a vancomycin-
heparin complex may have been formed, decreas-
ing vancomycin’s transplacental passage. HPLC
revealed appropriate and constant levels of
vancomycin in the maternal efﬂuence containing
0.5–1.0 unit/ml of heparin. Review of the HPLC
data revealed artifact present for placenta 3, falsely
elevating the clearance index to 0.08. Of note, the
presence of antipyrine
14C also interfered with the
HPLC and falsely elevated the concentration of
Table 1 Mean vancomycin concentrations (mg/ml),
troughs and peaks, in placentas 1–6
Placenta Trough Peak
1 – 51.5
2 16.4 33.0
3 11.7 33.0
4 7.7 40.1
51 4 . 8 –
6 8.0 30.0
Table 2 Mean vancomycin clearance indexes, troughs
and peaks, in placentas 1–6
Placenta Trough Peak
1 – 0.035
2 0.00 0.000
3 0.17 0.080
4 0.05 0.014
5 0.00 –
6 0.00 0.000
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14C was infused at
the end of the experiment after all the samples for
vancomycin were collected in the fetal and
maternal compartments.
Most drugs cross the placenta by simple
diffusion. Transplacental diffusion of substances
is dependent upon many factors, such as
molecular size or weight, ionic charge, lipid
solubility and the circulating concentration not
bound to plasma proteins
14. Approximately a
third to a half of vancomycin is bound to plasma
proteins and is unavailable for transfer
15.
Furthermore, hydrophilic substances cross more
slowly than lipophilic substances and the pla-
cental extracellular pores have limited surface
area. In addition, transfer of any substance or
drug through the pores is dependent upon its
molecular weight. Substances with a molecular
weight of less than 500 daltons will usually cross
the placenta
14 and rate of transfer is proportional
to molecular weight (i.e. a large complex
molecule will diffuse at a slower rate than a
smaller molecule). Vancomycin is a complex
tricyclic glycopeptide with a molecular weight of
approximately 1500 daltons
15. In our ex vivo
model, the transfer rate or clearance index for
vancomycin was almost zero for peak and trough
concentrations.
The pharmacokinetics of vancomycin may be
altered in vivo by the physiologic changes of
pregnancy. In non-pregnant subjects, 30–55% of
vancomycin is bound to plasma proteins and 90%
is excreted by glomerular ﬁltration
15,16. Plasma
proteins, glomerular ﬁltration rate and plasma
volume are increased during pregnancy, decreas-
ing the total unbound concentration of the drug
available to cross the placenta. This may further
decrease the concentration available for placental
transfer. In non-pregnant subjects, plasma levels
reach a concentration of 15–30 mg/ml approxi-
mately 1 h after intravenous administration of 1 g
vancomycin over 1–2 h.
Previous studies have shown that vancomycin
crosses membrane barriers only when infection
and inﬂammation are present
9,10,16. With menin-
gitis, cerebral spinal ﬂuid (CSF) levels of
vancomycin range from 7% to 30% of the serum
concentration
16. Without meningitis, CSF levels
are undetectable
16. In two studies, vancomycin
concentration reached therapeutic levels in the
fetal circulation when treating the mother for
overt amnionitis in a preterm gestation in hopes
of prolonging the pregnancy
9,10 and adequate
levels were obtained after multiple doses. The
administration of 1 or 2 doses of vancomycin may
be inadequate to obtain therapeutic levels in the
fetal compartment in the presence or absence of
inﬂammation.
In conclusion, our results show that there is
minimal or no transport of vancomycin into the
fetal compartment in the ex vivo placental
profusion model. In addition, vancomycin con-
centration and pharmacokinetics may be altered
by the normal physiologic changes of pregnancy
affecting placental passage. Therefore, additional
studies using vancomycin in pregnancy should be
undertaken to assess its effectiveness in GBS
chemoprophylaxis.
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